Connect Biopharma Holdings Ltd (CNTB) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Connect Biopharma Holdings Ltd stock $0.49, price $0.73, that is 32.3% below the price, quality 29 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $0.5500 – $28.50 · fair‑value band $0.3315 – $0.6205 · the $0.7287 price screens above the $0.4930 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Connect Biopharma Holdings in your weekly email
Every Wednesday you see whether Connect Biopharma Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States.
Show moreShow less
It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Stock analysis
Connect Biopharma Holdings Ltd (CNTB) currently trades at $0.7287, while our model-based Fair Value estimate is $0.4930, 32% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.3315 (bear) to $0.6205 (bull), the price of $0.7287 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Connect Biopharma Holdings Ltd reported revenue of $64.0K in FY2025 versus $0 in FY2021. Reported net income was −$55.5M in FY2025.
Key figures
Market cap $45.7M Micro · P/S ratio 18.0 · EPS (TTM) $−1.19 · Return on equity −141% · Return on assets (EBIT) −56.4% (5-year average) · Operating margin −636% · Revenue growth (YoY) +56.7% · Free cash flow −$51.6M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).
What moves the price
The share trades about 80% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −32%, CNTB screens richer than that median.
Fair Value models
Bear$0.3315Fair Value $0.4930Bull$0.6205
Price $0.7287 · Downside -32.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.3900$0.5800$0.730052
All 1 models by family
Asset-Based
NCAV (Graham)$0.3900$0.5800$0.730052
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, one officer or director bought shares worth $372,000, on May 29, 2026.
BuyJames HuangDirector2× since Mar 31, 2026: 1,310,000 shares, avg. $3.34$4.4MMay 29, 2026
Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Connect Biopharma Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks
Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score29 · Bottom 25%
Fair Value upside−32.3% · Above median
Profitability
Return on assets−98.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)56.7% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.09× · Cheapest 25%
P/S (12 months)15.49× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Connect Biopharma Holdings Ltd (CNTB) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $0.4930 versus a price of $0.7287, about 32% lower (overvalued).
What is the fair value of CNTB?
Our model-based fair value for Connect Biopharma Holdings Ltd is $0.4930 (as of Nov 9, 2026), built from audited fundamentals. The current price: $0.7287.
What is the quality score of CNTB?
Connect Biopharma Holdings Ltd has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Connect Biopharma Holdings Ltd (CNTB)?
Our model-based price target is the fair value of $0.4930 (as of Nov 9, 2026) from 1 valuation models. Cautious scenario $0.3315, optimistic scenario $0.6205. It is a calculation from audited fundamentals, not an analyst target.
What is the Connect Biopharma Holdings Ltd stock forecast for 2026?
Our models put fair value at $0.4930, about 32% lower versus a price of $0.7287 (overvalued). Cautious scenario $0.3315, optimistic scenario $0.6205. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Connect Biopharma Holdings Ltd (CNTB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Connect Biopharma Holdings Ltd it is $0.4930 per share (as of Nov 9, 2026), against a price of $0.7287. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Connect Biopharma Holdings Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, CNTB trades above its calculated fair value: price $0.7287, fair value $0.4930, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CNTB?
No. The price is what the market pays today ($0.7287); the fair value is what the company's own numbers justify ($0.4930). For Connect Biopharma Holdings Ltd the two are $0.2357 per share apart. That gap is exactly why we show both numbers side by side.
How much is Connect Biopharma Holdings Ltd worth?
The market values Connect Biopharma Holdings Ltd at about $45.7M (market capitalisation, as of Nov 9, 2026). Per share that is $0.7287; our models calculate a fair value of $0.4930 per share.
What do the bullish and bearish scenarios say about CNTB?
Our models span a range for Connect Biopharma Holdings Ltd: cautious scenario $0.3315, base $0.4930, optimistic $0.6205 per share (as of Nov 9, 2026, price $0.7287). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Connect Biopharma Holdings Ltd (CNTB)?
Balance-sheet figures for Connect Biopharma Holdings Ltd (as of Nov 9, 2026): return on equity −140.5%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is CNTB from its 52-week high?
Connect Biopharma Holdings Ltd trades at $0.7287, about 80% below its 52-week high of $3.69 and at the low of $0.7287 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.4930 is for.
Which stocks are comparable to Connect Biopharma Holdings Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Connect Biopharma Holdings Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price $0.7287, calculated fair value $0.4930 (−32%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CNTB calculated?
We run Connect Biopharma Holdings Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.4930 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Connect Biopharma Holdings Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Connect Biopharma Holdings Ltd (CNTB)?
The closing price on Nov 6, 2026 was $0.7287. Our model-based fair value is $0.4930, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Connect Biopharma Holdings Ltd right now?
The price sits above even our optimistic bull case ($0.6205). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.3315 to $0.6205) leaves room in how you read the outcome.
Key figures of Connect Biopharma Holdings Ltd
How large is the market capitalisation of Connect Biopharma Holdings Ltd (CNTB)?
The market capitalisation of Connect Biopharma Holdings Ltd is $45.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Connect Biopharma Holdings Ltd (CNTB)?
The price-to-sales ratio of Connect Biopharma Holdings Ltd is 18.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Connect Biopharma Holdings Ltd (CNTB)?
Earnings per share at Connect Biopharma Holdings Ltd are $−1.19. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Connect Biopharma Holdings Ltd (CNTB)?
The return on equity (ROE) of Connect Biopharma Holdings Ltd is −141% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Connect Biopharma Holdings Ltd (CNTB)?
On an EBIT basis the return on assets of Connect Biopharma Holdings Ltd is −56.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Connect Biopharma Holdings Ltd (CNTB)?
The operating margin of Connect Biopharma Holdings Ltd is −636% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Connect Biopharma Holdings Ltd (CNTB)?
Revenue at Connect Biopharma Holdings Ltd is growing +56.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Connect Biopharma Holdings Ltd (CNTB) generate?
The free cash flow of Connect Biopharma Holdings Ltd is −$51.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Connect Biopharma Holdings Ltd (CNTB) hold?
Connect Biopharma Holdings Ltd holds more cash than debt, $37.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Connect Biopharma Holdings Ltd in the live analysis
One click puts Connect Biopharma Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026
